Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
This invention relates to an animal model showing several behavioral and neuropathological features of schizophrenia. More
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
"A comprehensive set of samples in various diseases. The resource consists of DNA samples from 16 diseases (Type I diabetes, Type II diabetes, Asthma, Colorectal Cancer, Breast Cancer, Prostate Cancer, Alzheimer's disease, Parkinson's disease... More
The SNP identified in the SCN1A gene can be used as a genotype test to aid in the correct dosing of anti-epileptic drugs thereby avoiding debilitating adverse drug effects. More
These compounds have demonstrated high affinity and selectivity for the dopamine transporter over other monoamine transponders as well as muscarinic receptors, without a significant cocaine-like behavioral profile. More
A new A new treatment for chronic pain, Arrhythmia and degeneration and behaviour disease (such as Schizophrenia, mania-depression, Alzheimer's and Parkinson's diseases). More
Assay should predict susceptibility to schizophrenia even before clinical symptoms are apparent, if aberrant ErbB function during development is a cause of schizophrenia and that function is expressed in peripheral blood cells throughout life. More
Leverage the First Known Schizophrenia Susceptibility Gene for New Treatments & Diagnostics More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Addiction
- Alcoholism
- Anorexia nervosa
- Anxiety
- Bipolar disorder
- Bulimia nervosa
- Cocaine addiction
- Depression
- Mental health (other)
- Obsessive compulsive disorder
- Opioid dependency
- Panic disorder
- Phobia, social
- Post-traumatic stress disorder
- Psychosis
- Schizophrenia
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us